Senseonics Holdings Inc. (SENS) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, SENS scores 41 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the RQD rating, this reflects ROIC of -35% and an FCF yield of -11.47%. For a prospective investor, the core issue is that the business is consuming cash rather than generating it, so the equity case depends on future operating improvement that the current numbers do not yet show.
• Whale 13F Flow: 15 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. It is the strongest pillar, suggesting some professional interest, though the source data does not break out the size or direction of those positions.
• Insider Conviction: 3 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider signaling, which a prospective investor may weigh as a lack of visible conviction from people with the most information.
• Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. The stock is assessed as moving in line with the broader market, offering no defensive cushion in a downturn.
• Forensic Balance Sheet: 8 / 20. Per the RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. These are moderate readings that do not signal acute distress but do not provide strong balance-sheet comfort either.

Taken together, the rating points to a company with a cash-burning operating model, moderate forensic health, and a valuation that depends heavily on a turnaround that has not yet appeared in reported results. The upside case rests on margin improvement and sustained institutional interest; the downside risk is continued burn that erodes the cash position.

Per the SEC financials, revenue rose from $22.4M in FY 2023 to $35.3M in FY 2025, but operating losses remained large in every period shown, and net margin per the market data is -60%. Operating margin is also -60% and ROIC is -35%. Cash declined from $74.6M at FY 2024 to $40.2M at FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, indicating moderate forensic health, with Debt/Equity at 0.5.

Per the recent news and catalysts feed, the most recent items (all tagged as market wire, yellow signal) include: a Stock Titan item reporting a one-year diabetes monitor designed without an external transmitter entering human testing; a Stock Titan item noting two November talks in New York; and a Barclays price target of USD 10 reported by ad-hoc-news.de. Other items are general market coverage from Yahoo Finance, Kalkine Media, and Yahoo! Finance Canada. The human-testing entry is the most substantive product catalyst; the Barclays target is the only specific valuation reference. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Per the analyst data section, no information is available. Per the holders section, no information is available. Consensus rating and price targets from the Barclays item are the only analyst reference in the feed, but no consensus or full target set is provided. Form 4 insider, 13F institutional, and Congressional trade detail is Not available in source data beyond the RQD pillar scores noted above.

• What drives the gap between the $35.3M FY 2025 revenue and the -$68.3M operating loss, and when does management expect that gap to narrow?
• Why did cash decline by roughly $34.4M from FY 2024 to FY 2025, and how much runway remains at the current burn rate?
• What is the size and direction of institutional and options positioning behind the 13F pillar score?
• Does the Barclays USD 10 target reflect a full analyst coverage set, and what assumptions underpin it?
• What are the commercial milestones and regulatory timelines associated with the human-testing monitor?